Literature DB >> 11896268

Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.

Christopher Dye1, Brian G Williams, Marcos A Espinal, Mario C Raviglione.   

Abstract

Multidrug-resistant tuberculosis (MDR) is perceived as a growing hazard to human health worldwide. Judgments about the true scale of the problem, and strategies for containing it, need to come from a balanced appraisal of the epidemiological evidence. We conclude in this review that MDR is, and will probably remain, a locally severe problem; that epidemics can be prevented by fully exploiting the potential of standard short-course chemotherapy (SCC) based on cheap and safe first-line drugs; and that best-practice SCC may even reduce the incidence of MDR where it has already become endemic. On the basis of the available, imperfect data, we recommend a three-part response to the threat of MDR: widespread implementation of SCC as the cornerstone of good tuberculosis control, improved resistance testing and surveillance, and the careful introduction of second-line drugs after a sound evaluation of cost, effectiveness, and feasibility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896268     DOI: 10.1126/science.1063814

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  84 in total

1.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China.

Authors:  Jun Yue; Wei Shi; Jingping Xie; Yao Li; Erliang Zeng; Honghai Wang
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

2.  Continued low rates of transmission of Mycobacterium tuberculosis in Norway.

Authors:  Ulf R Dahle; Per Sandven; Einar Heldal; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

3.  The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Authors:  Gwenan M Knight; Caroline Colijn; Sourya Shrestha; Mariam Fofana; Frank Cobelens; Richard G White; David W Dowdy; Ted Cohen
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

4.  AccD6, a member of the Fas II locus, is a functional carboxyltransferase subunit of the acyl-coenzyme A carboxylase in Mycobacterium tuberculosis.

Authors:  Jaiyanth Daniel; Tae-Jin Oh; Chang-Muk Lee; Pappachan E Kolattukudy
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

5.  Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China.

Authors:  Min Zhang; Jun Yue; Yan-Ping Yang; Hong-Mei Zhang; Jian-Qiang Lei; Rui-Liang Jin; Xue-Lian Zhang; Hong-Hai Wang
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  Variants of the SFTPA1 and SFTPA2 genes and susceptibility to tuberculosis in Ethiopia.

Authors:  S Malik; C M T Greenwood; T Eguale; A Kifle; J Beyene; A Habte; A Tadesse; H Gebrexabher; S Britton; E Schurr
Journal:  Hum Genet       Date:  2005-11-15       Impact factor: 4.132

7.  Molecular mechanisms by which rRNA mutations confer resistance to clindamycin.

Authors:  Jacob Poehlsgaard; Peter Pfister; Erik C Böttger; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance.

Authors:  Deus Lukoye; Fred A Katabazi; Kenneth Musisi; David P Kateete; Benon B Asiimwe; Moses Okee; Moses L Joloba; Frank G J Cobelens
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

Review 9.  Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.

Authors:  Kwonjune J Seung; Salmaan Keshavjee; Michael L Rich
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-27       Impact factor: 6.915

Review 10.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.